MANKIND PHARMA
|
|
| BOM : 543904     NSE : MANKIND     | |
| LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Nov 28,2025 |
|
Price(EOD): ₹ 2,251.85
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 92,956.37 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| MANKIND PHARMA | 1.4% | -7.9% | -13% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.8% | 6.7% | 2.8% |
| DIVIS LABORATORIES | 1.9% | -0.5% | 6.9% |
| CIPLA | 1.8% | -3.2% | 2.1% |
| TORRENT PHARMACEUTICALS | 0.1% | 3.4% | 15.8% |
| DR REDDYS LABORATORIES | 2.7% | 0.4% | 3.4% |
| ZYDUS LIFESCIENCES | 1.7% | -5.9% | -1.6% |
| LUPIN | 4.1% | 6.4% | 1.8% |
| AUROBINDO PHARMA | 2.5% | 10% | 0.6% |
FUNDAMENTAL ANALYSIS OF MANKIND PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF MANKIND PHARMA
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
52.61
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,767.06 Cr
[Latest Qtr - Sep2025 - Consolidated Results ] 6.51
P/B Calculated based on Book Value of Rs 14,288.70 Cr
[Latest Year - Mar2025 - Consolidated Results ] 6.85
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 13,576.90 Cr
[Latest Qtr - Sep2025 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
4915% 4313% -28% |
SHARE PRICE MOMENTUM OF MANKIND PHARMA
MANKIND PHARMA vs SENSEX
DEBT OF MANKIND PHARMA
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2025 2024 2023 Avg_3yrs |
0.48 0 0 0.16 |
0.58 0.02 0.02 0.21 |
|
[Last Annual Data : Mar2025]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF MANKIND PHARMA
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Sep2025 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF MANKIND PHARMA
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
3.55% 8.81% 15.7% 17.31% |
20.77% 8.75% -26.74% -21.38% |
| QtrlyTrend |
4 | |
| Latest Qtr: Sep2025 | ||
| Quarterly Result Analysis → | ||
MANKIND PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE HEALTHCARE | 1.1% | 0.2% | 3.5% |
| BSE 200 EQUAL WEIGHT | 0.7% | 0.5% | 5.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY PHARMA | 1.9% | 3.4% | 3.7% |
| NIFTY HEALTHCARE INDEX | 1.4% | 1.3% | 6.6% |
| NIFTY MIDCAP SELECT | 1.4% | 5.1% | 11.7% |
| NIFTY MIDCAP 50 | 1.3% | 2.9% | 11.7% |
| NIFTY MIDCAP 100 | 1.3% | 2.1% | 9.2% |
You may also like the below Video Courses
FAQ about MANKIND PHARMA
Is MANKIND PHARMA good for long term investment?
As on Nov 28,2025, the Fundamentals of MANKIND PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of MANKIND PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is MANKIND PHARMA UnderValued or OverValued?
As on Nov 28,2025, MANKIND PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of MANKIND PHARMA ?
As on Nov 28,2025, the Intrinsic Value of MANKIND PHARMA is Rs. 51.03 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 44.90
Fair Value [Median EV / Sales Model] : Rs. 51.03
Fair Value [Median Price / Sales Model] : Rs. 3,109.50
Estimated Median Fair Value of MANKIND PHARMA : Rs. 51.03
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.